Why Pfizer (PFE) Stock Is Lower Today

NEW YORK (TheStreet) -- Pfizer (PFE) stock is slipping on Monday after the company posted first-quarter profits 15% lower than a year earlier and revenue down 9%.

By midmorning, shares had dropped 2.1% to $30.11.

The pharmaceuticals company reported net income of $2.3 billion over the three months to March. Excluding one-time items, net income of 57 cents a share beat expectations by 2 cents, according to analysts polled by Thomson Reuters. 

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Revenue of $11.3 billion fell short of analysts' estimates of $12.1 billion.

The weaker-than-expected report comes days after its latest offer to purchase British drugmaker AstraZeneca for $106 billion was rejected.

Pfizer has recently suffered lower revenues and earnings as key patents expire, giving way to the development of cheaper generic brands. This has been especially true for Pfizer's cholesterol drug Lipitor, the patent for which expired in 2011.

Must Read: Warren Buffett's 10 Favorite Growth Stocks

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.


WATCH: More market update videos on TheStreet TV | More videos from Keris Alison Lahiff

If you liked this article you might like

The 6 Medications Being Used to Tackle the Opioid Epidemic

Dow, S&P 500 Set New Records as Fed Moves to Unwind Balance Sheet

Stocks In Negative Territory as Chances for December Hike Surge

The Wait for 'Milestone' Fed Meeting Keeps Stocks in Flux